The Rise Of The pCPA Heralds More Pricing Pressure In Canada
This article was originally published in Scrip
It looks as though there could be yet more pricing pressure on companies selling drugs in Canada after the country's federal government said it would be joining the pan-Canadian Pharmaceutical Alliance, the body that negotiates lower drugs prices for Canada's many publicly funded drug plans.
You may also be interested in...
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.